Related Experiment Video
Updated: Jun 13, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Immune checkpoint inhibitors for first-line treatment of advanced esophageal squamous cell carcinoma
Maria Alsina1, Tania Fleitas-Kanonnikoff2
1Medical Oncology Department, Hospital Universitario de Navarra, Translational Medical Oncology Investigational Group, Navarrabiomed - IdiSNA, C/ Irunlarrea 3, 35008 Pamplona, Spain.
Abstract:
Immunotherapy has revolutionized the treatment landscape of esophageal squamous cell carcinoma. He et al. present the final results of the randomized phase 3 ESCORT-1st trial, confirming positive survival outcomes when adding the anti-PD1 inhibitor camrelizumab to first-line chemotherapy treatment in Chinese patients with esophageal squamous cell cancer.1.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
Mitogens and the Cell Cycle
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

